Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Curr Drug Targets. 2021;22(13):1536-1547. doi: 10.2174/1389450121999201228212842.
Early in December 2019, mass sufferers due to Novel Coronavirus Pneumonia (SARS-CoV-2) in Wuhan (China) roused worldwide concern. Hardly any drugs showed the light of hope concerning the depletion in the period of treatment, and virological suppression became ineffective. Furthermore, numerous sufferers have undergone off-label use or compassionate use treatments as well as antiretroviral, antiparasitic agents, anti-inflammatory compounds, and convalescent plasma in either oral/parenteral route. This study aims to compile and analyze the effectiveness of Remdesivir and Hydroxychloroquine and give an insight into their drug profile in the treatment and management of COVID-19 patients.
Relevant literature was searched from PubMed, Crossref, Springer, Bentham Sciences, Google Scholar, DOAJ, ScienceDirect, and MEDLINE by using keywords like COVID-19, SARS-- COV-2, Remdesivir, and Hydroxychloroquine. Appropriate peer-reviewed articles were studied and compiled for this review paper. The figures were prepared by using ChemOffice 2016 (Chem- Draw Professional 2016) and Microsoft Office.
This study indicates that 5 out of 10 works of literature find that Remdesivir leads to a reduction in recovery time, and the remaining 5 pieces of literature found Remdesivir to have no variance and have limitations. However, 6 out of 12 articles presented an increased chance of survival or reduction in recovery time due to hydroxychloroquine, while the remaining 6 presented hydroxychloroquine having no effect.
There is a need to assess more pharmacokinetics and randomized controlled trials (RCT) for Remdesivir and Hydroxychloroquine. Studies should be conducted in different combinations along with Hydroxychloroquine and Remdesivir to obtain better results.
2019 年 12 月初，武汉（中国）新型冠状病毒肺炎（SARS-CoV-2）大规模发病引起了全球关注。在治疗期间，几乎没有任何药物显示出希望，病毒学抑制变得无效。此外，许多患者已经接受了标签外使用或同情使用治疗，以及抗病毒、抗寄生虫药物、抗炎化合物和恢复期血浆的口服/肠胃外途径。本研究旨在编译和分析瑞德西韦和羟氯喹的有效性，并深入了解它们在 COVID-19 患者治疗和管理中的药物概况。
使用 COVID-19、SARS-CoV-2、瑞德西韦和羟氯喹等关键词，从 PubMed、Crossref、Springer、Bentham Sciences、Google Scholar、DOAJ、ScienceDirect 和 MEDLINE 等数据库中搜索相关文献。对适当的同行评议文章进行研究和编译，以撰写这篇综述论文。使用 ChemOffice 2016（Chem-Draw Professional 2016）和 Microsoft Office 制作图表。
本研究表明，10 篇文献中有 5 篇表明瑞德西韦可缩短康复时间，其余 5 篇文献发现瑞德西韦没有差异且存在局限性。然而，12 篇文章中有 6 篇表明羟氯喹可提高生存率或缩短康复时间，而其余 6 篇则表明羟氯喹没有效果。
需要评估瑞德西韦和羟氯喹的更多药代动力学和随机对照试验（RCT）。应该进行不同组合的研究，包括羟氯喹和瑞德西韦，以获得更好的结果。
